News stories about EXACT Sciences (NASDAQ:EXAS) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. EXACT Sciences earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.9574703451184 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
NASDAQ EXAS opened at $37.84 on Friday. The company has a quick ratio of 6.77, a current ratio of 7.15 and a debt-to-equity ratio of 0.01. The company has a market cap of $4,898.13, a PE ratio of -38.22 and a beta of 0.87. EXACT Sciences has a one year low of $22.30 and a one year high of $63.60.
EXACT Sciences (NASDAQ:EXAS) last posted its earnings results on Thursday, February 22nd. The medical research company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.09. The firm had revenue of $87.41 million during the quarter, compared to the consensus estimate of $87.42 million. EXACT Sciences had a negative return on equity of 24.13% and a negative net margin of 43.01%. The company’s quarterly revenue was up 148.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.34) EPS. sell-side analysts expect that EXACT Sciences will post -0.92 EPS for the current year.
A number of brokerages have issued reports on EXAS. Bank of America set a $67.00 price objective on shares of EXACT Sciences and gave the company a “buy” rating in a report on Monday, January 8th. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a report on Tuesday, January 16th. William Blair reaffirmed a “buy” rating on shares of EXACT Sciences in a report on Tuesday, January 2nd. Finally, Goldman Sachs began coverage on shares of EXACT Sciences in a report on Monday, January 29th. They set a “neutral” rating and a $51.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $52.84.
In related news, insider Kevin T. Conroy sold 125,402 shares of the firm’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $52.79, for a total value of $6,619,971.58. Following the completion of the sale, the insider now directly owns 955,454 shares in the company, valued at $50,438,416.66. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP D Scott Coward sold 2,122 shares of the firm’s stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $40.12, for a total value of $85,134.64. The disclosure for this sale can be found here. Insiders have sold a total of 449,995 shares of company stock valued at $21,876,323 over the last quarter. Corporate insiders own 4.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “EXACT Sciences (EXAS) Given Daily News Impact Rating of 0.19” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/exact-sciences-exas-given-daily-news-impact-rating-of-0-19.html.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.